View in EDS

The impact of COVID-19 on antipsychotic prescriptions for patients with schizophrenia in Australia.

Saved in:
Bibliographic Details
Title: The impact of COVID-19 on antipsychotic prescriptions for patients with schizophrenia in Australia.
Authors: Kisely, Steve, Dangelo-Kemp, Dante, Taylor, Mark, Liu, Dennis, Graham, Simon, Hartmann, Jodie, Colman, Sam
Source: Australian & New Zealand Journal of Psychiatry. Jun2022, Vol. 56 Issue 6, p642-647. 6p.
Subjects: Drug therapy for schizophrenia, Retrospective studies, Drug prescribing, Descriptive statistics, Medical referrals, Stay-at-home orders, Physician practice patterns, COVID-19 pandemic, Antipsychotic agents
Geographic Terms: Australia
Abstract: Objective: To assess the impact, in the Australian setting, of the COVID-19 lockdown on antipsychotic supplies for patients with schizophrenia following a prescription from a new medical consultation when compared to the same periods in the previous 4 years. A secondary objective was to assess the volume of all antipsychotic supplies, from new and repeat prescriptions, over these same periods. Methods: A retrospective pharmaceutical claims database study was undertaken, using the Department of Human Services Pharmaceutical Benefits Scheme 10% sample. The study population included all adult patients with three or more supplies of oral or long-acting injectable antipsychotics for the treatment of schizophrenia at any time between 1 June 2015 and 31 May 2020. The primary outcome compared volumes of dispensed antipsychotics from new prescriptions (which require a medical consultation) between 1 April and 31 May each year from 2016 to 2020. This was to analyse the period during which the Australian Government imposed a lockdown due to COVID-19 (April to May 2020) when compared the same periods in previous years. Results: There was a small (5.7%) reduction in the number of antipsychotics dispensed from new prescriptions requiring a consultation, from 15,244 to 14,372, between April and May 2019 and the same period in 2020, respectively. However, this reduction was not statistically significant (p = 0.75) after adjusting for treatment class, age, gender, location and provider type. Conclusion: The COVID-19 restrictions during April and May 2020 had no significant impact on the volume of antipsychotics dispensed from new prescriptions for patients with schizophrenia when compared to the volume of antipsychotics dispensed from new prescriptions during the same period in previous years. [ABSTRACT FROM AUTHOR]
Copyright of Australian & New Zealand Journal of Psychiatry is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 157071025
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The impact of COVID-19 on antipsychotic prescriptions for patients with schizophrenia in Australia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Kisely%2C+Steve%22">Kisely, Steve</searchLink><br /><searchLink fieldCode="AR" term="%22Dangelo-Kemp%2C+Dante%22">Dangelo-Kemp, Dante</searchLink><br /><searchLink fieldCode="AR" term="%22Taylor%2C+Mark%22">Taylor, Mark</searchLink><br /><searchLink fieldCode="AR" term="%22Liu%2C+Dennis%22">Liu, Dennis</searchLink><br /><searchLink fieldCode="AR" term="%22Graham%2C+Simon%22">Graham, Simon</searchLink><br /><searchLink fieldCode="AR" term="%22Hartmann%2C+Jodie%22">Hartmann, Jodie</searchLink><br /><searchLink fieldCode="AR" term="%22Colman%2C+Sam%22">Colman, Sam</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Australian+%26+New+Zealand+Journal+of+Psychiatry%22">Australian & New Zealand Journal of Psychiatry</searchLink>. Jun2022, Vol. 56 Issue 6, p642-647. 6p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Drug+therapy+for+schizophrenia%22">Drug therapy for schizophrenia</searchLink><br /><searchLink fieldCode="DE" term="%22Retrospective+studies%22">Retrospective studies</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+prescribing%22">Drug prescribing</searchLink><br /><searchLink fieldCode="DE" term="%22Descriptive+statistics%22">Descriptive statistics</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+referrals%22">Medical referrals</searchLink><br /><searchLink fieldCode="DE" term="%22Stay-at-home+orders%22">Stay-at-home orders</searchLink><br /><searchLink fieldCode="DE" term="%22Physician+practice+patterns%22">Physician practice patterns</searchLink><br /><searchLink fieldCode="DE" term="%22COVID-19+pandemic%22">COVID-19 pandemic</searchLink><br /><searchLink fieldCode="DE" term="%22Antipsychotic+agents%22">Antipsychotic agents</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Australia%22">Australia</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Objective: To assess the impact, in the Australian setting, of the COVID-19 lockdown on antipsychotic supplies for patients with schizophrenia following a prescription from a new medical consultation when compared to the same periods in the previous 4 years. A secondary objective was to assess the volume of all antipsychotic supplies, from new and repeat prescriptions, over these same periods. Methods: A retrospective pharmaceutical claims database study was undertaken, using the Department of Human Services Pharmaceutical Benefits Scheme 10% sample. The study population included all adult patients with three or more supplies of oral or long-acting injectable antipsychotics for the treatment of schizophrenia at any time between 1 June 2015 and 31 May 2020. The primary outcome compared volumes of dispensed antipsychotics from new prescriptions (which require a medical consultation) between 1 April and 31 May each year from 2016 to 2020. This was to analyse the period during which the Australian Government imposed a lockdown due to COVID-19 (April to May 2020) when compared the same periods in previous years. Results: There was a small (5.7%) reduction in the number of antipsychotics dispensed from new prescriptions requiring a consultation, from 15,244 to 14,372, between April and May 2019 and the same period in 2020, respectively. However, this reduction was not statistically significant (p = 0.75) after adjusting for treatment class, age, gender, location and provider type. Conclusion: The COVID-19 restrictions during April and May 2020 had no significant impact on the volume of antipsychotics dispensed from new prescriptions for patients with schizophrenia when compared to the volume of antipsychotics dispensed from new prescriptions during the same period in previous years. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Australian & New Zealand Journal of Psychiatry is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=157071025
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/00048674211025716
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 6
        StartPage: 642
    Subjects:
      – SubjectFull: Drug therapy for schizophrenia
        Type: general
      – SubjectFull: Retrospective studies
        Type: general
      – SubjectFull: Drug prescribing
        Type: general
      – SubjectFull: Descriptive statistics
        Type: general
      – SubjectFull: Medical referrals
        Type: general
      – SubjectFull: Stay-at-home orders
        Type: general
      – SubjectFull: Physician practice patterns
        Type: general
      – SubjectFull: COVID-19 pandemic
        Type: general
      – SubjectFull: Antipsychotic agents
        Type: general
      – SubjectFull: Australia
        Type: general
    Titles:
      – TitleFull: The impact of COVID-19 on antipsychotic prescriptions for patients with schizophrenia in Australia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kisely, Steve
      – PersonEntity:
          Name:
            NameFull: Dangelo-Kemp, Dante
      – PersonEntity:
          Name:
            NameFull: Taylor, Mark
      – PersonEntity:
          Name:
            NameFull: Liu, Dennis
      – PersonEntity:
          Name:
            NameFull: Graham, Simon
      – PersonEntity:
          Name:
            NameFull: Hartmann, Jodie
      – PersonEntity:
          Name:
            NameFull: Colman, Sam
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: Jun2022
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 00048674
          Numbering:
            – Type: volume
              Value: 56
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Australian & New Zealand Journal of Psychiatry
              Type: main
ResultId 1